Sugi Predict

Sugi Predict / Compounds / SCHEMBL2331670

SCHEMBL2331670

SCHEMBL2331670

Cc1cc(C#N)ccc1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 8/20 0.50
▸ TP53 P04637 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ PDE10A Q9Y233 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ CYP2A6 P11509 1/20 0.46
▸ CA12 O43570 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ CA3 P07451 1/20 0.46
▸ CA6 P23280 1/20 0.46
▸ CA9 Q16790 1/20 0.46
▸ CA14 Q9ULX7 1/20 0.46
▸ ESR1 P03372 6/20 0.45
▸ ESR2 Q92731 4/20 0.45
▸ MMP3 P08254 1/20 0.41
▸ TTR P02766 1/20 0.41
▸ ALB P02768 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2786046 0.84 AR (0.57) ARTP53TDP1PDE10AALDH1A1
SCHEMBL31294509 0.82 TSHR (0.46) ARALDH1A1CYP2A6CA12CA2
SCHEMBL68647 0.82 TSHR (0.46) ARALDH1A1CYP2A6CA12CA2
SCHEMBL20056706 0.82 AR (0.51) ARTP53TDP1ESR2MMP3
SCHEMBL12620795 0.81 TP53 (0.54) ARTP53TDP1PDE10AALDH1A1
SCHEMBL10248395 0.79 HSD17B1 (0.59) ARESR2CYP3A4CYP2D6CYP2C19
SCHEMBL29449995 0.78 CA12 (0.52) ARTP53ALDH1A1CYP2A6CA12
SCHEMBL1436903 0.78 CYP2A6 (0.52) ARALDH1A1CYP2A6CA12CA2
SCHEMBL29814587 0.78 CYP2A6 (0.52) ARALDH1A1CYP2A6CA12CA2
SCHEMBL217250 0.78 CA12 (0.52) ARTP53ALDH1A1CYP2A6CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117430616-A Pyrimido ring compound containing deuterated methyl, preparation method and application thereof 复旦大学 2024-01-23 — — CN claimed
CN-109574952-B Synthetic method of febuxostat intermediate 安徽省庆云医药股份有限公司 2022-04-01 — — CN claimed
CN-109574952-A A kind of synthetic method of febuxostat intermediate 安徽省庆云医药股份有限公司 2019-04-05 — — CN claimed
CN-102229581-B Preparation method for febuxostat intermediate ZOU QIAOGEN 2013-07-03 — — CN claimed
CN-102229581-A Preparation method for febuxostat intermediate QIAOGEN ZOU 2011-11-02 — — CN claimed
US-20260137680-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LTD (GB) 2026-05-21 — — US disclosed
US-12595251-B2 Amidines and amidine analogs for the treatment of bacterial infections and potentiation antibiotics GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2026-04-07 — — US disclosed
EP-4583867-A2 SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE Latigo Biotherapeutics, Inc. (US) 2025-07-16 — — EP disclosed
CN-120040369-A Oxadiazole amide c-Myc inhibitor and preparation method and application thereof 上海深势唯思科技有限责任公司 2025-05-27 — — CN disclosed
CN-119968366-A Oxadiazole derivatives, methods of preparation and use thereof in the treatment of inflammatory diseases 西特瑞治疗有限公司 2025-05-09 — — CN disclosed
EP-4543875-A1 OXADIAZOLE DERIVATIVES, PREPARATION PROCESS THEREOF AND THEIR USE IN TREATING INFLAMMATORY DISEASES Sitryx Therapeutics Limited (GB) 2025-04-30 — — EP disclosed
CN-119894509-A Sodium channel blocking compounds, derivatives thereof, and methods of use thereof 拉堤果生物医疗股份有限公司 2025-04-25 — — CN disclosed
EP-0853618-A1 SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1998-07-22 — — EP disclosed
US-5643929-A TREATMENT OF PICORNAVIRAL OR RHINOVIRUS AND CHEMICAL INTERMEDIATES SANOFI WINTHROP, INC. (US) 1997-07-01 — — US disclosed
WO-1996040679-A1 SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) 1996-12-19 — — WO disclosed
US-5464848-A 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents STERLING WINTHROP INC. (US) 1995-11-07 — — US disclosed
US-5116987-A METHOD OF PREPARING CHROMAN DERIVATIVES, AND SYNTHESIS INTERMEDIATES SANOFI (FR) 1992-05-26 — — US disclosed
US-5071991-A METHOD OF PREPARING CHROMAN DERIVATIVES, AND SYNTHESIS INTERMEDIATES SANOFI (FR) 1991-12-10 — — US disclosed
US-5059610-A QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-10-22 — — US disclosed
US-4920132-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260137680-A1 NOVEL COMPOUNDS CCR1, CCR4, CCR3 AR 2287/4885TP53 2073/4885TDP1 2040/4885
US-12595251-B2 Amidines and amidine analogs for the treatment of bacterial infections and potentiation antibiotics CLIC1, CBR3, CBR1 AR 3082/4885TP53 4818/4885TDP1 4213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.